Therapeutic Antibodies

Baby on a respirator - RSV
#AstraZeneca #FDA #Monoclonal antibodies #Paediatrics #Respiratory syncytial virus

Monoclonal antibody to prevent RSV in babies approved in US

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. The drug is also approved in children up to 24 months of age who… Read More

#News #Regulatory

Monoclonal antibodies
#Astellas Pharma #Cancer research #EMA #Gastrointestinal #Monoclonal antibodies #Oncology

EMA reviews monoclonal antibody for gastric cancer

The European Medicines Agency (EMA) has accepted for regulatory review Astellas Pharma’s marketing authorisation application (MAA) for zolbetuximab, an investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody. The application is for authorisation as a first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose… Read More

#News #Regulatory

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Antibody drug conjugate (ADC) #Biocytogen Pharmaceuticals #License agreement #Pheon Therapeutics #Therapeutic Antibodies

Licence agreement to develop ADCs for hard-to-treat cancers 

Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics.   Under the terms of the agreement, Pheon… Read More

#News

Therapeutic antibodies
#Bio-Rad Laboratories #Guide #Therapeutic Antibodies

Latest DDW Guide: Exclusive insight into therapeutic antibodies  

DDW has published the latest addition to its Guide Series, ‘Where is the innovation and opportunity in the therapeutic antibody market and how is it evolving?’ It is sponsored by Bio-Rad Laboratories.   In this free, exclusive guide, you will read:  The future of therapeutic… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

Monoclonal antibody
#Bayer #Evotec #Kidney disease #Monoclonal antibodies #Phase I trial

First patient dosed in trial of antibody for kidney disease

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market… Read More

#News

Genetic engineering concept with medication capsule with human brain diagram at programming language background
#Antibody #Drug discovery #Immuno-oncology #Therapeutic Antibodies #Therapeutics

DDW Summer 2023 issue out now

The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies.  Featuring a Therapeutic Spotlight on Immuno-oncology, the magazine is available to download free here and read for free on the DDW App.  You can also… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

Cancer immuno-oncology
#AI / data analytics / healthtech / informatics #Bispecific Antibodies #Bispecific therapeutics #Cambridge Healthtech Institute #Cancer immunotherapy #Events #Immuno-oncology #Next generation sequencing

Immuno-Oncology Summit Europe 2023: Programme highlights 

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. DDW’s Megan Thomas shares highlights from the event programmes.   Programmes   This year’s summit was made up of conference programmes, which included: Modulating the Tumour Microenvironment; Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and… Read More

#Cancer Research #Exclusive Content #Opinion

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

#Alchemab Therapeutics #Alzheimer's #Antibodies #Therapeutics

Alchemab unveils newly discovered Alzheimer’s candidate 

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate.   The data was announced at the Antibody Industrial Symposium in Tours, France, June 22-23, 2023.  ATLX-1088 is a potential… Read More

#News

T cells
#Antibodies #Cancer research #Immunotherapy #Oncology #T cell activation #Transcriptomics

Discovery could lead to more efficient cancer therapies

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer… Read More

#Cancer Research #News

Peanuts
#Allergy #Antibodies #Antibody #IgGenix #Monoclonal antibodies

Could a monoclonal antibody treat peanut allergy?

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies… Read More

#News

B-cells in multiple myeloma
#Bispecific Antibodies #Cancer research #Immunotherapy #IOME Bio

IOME Bio’s science represents breakthrough in cancer research 

IOME Bio, a seed stage biotechnology company focused on overcoming tumour resistance to immune checkpoint inhibition, has published its foundational research by founders Dr Arlene Sharpe and Dr Dennis Kasper in Nature.   By providing evidence of its therapeutic relevance, it reveals insights into the importance… Read More

#News